Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.56 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.48 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | RORB | Q92753 | 2/20 | 0.47 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787052 | 0.88 | PDE4B (0.52) | PDE4DPDE4BNPC1MAPTTSHR | |
| SCHEMBL24518295 | 0.88 | PTGES2 (0.47) | PDE4DPDE4BPTGES2ERN1NPC1 | |
| SCHEMBL29634149 | 0.87 | PTGDR2 (0.57) | PDE4DPTGES2ERN1TSHRSMN1; SMN2 | |
| SCHEMBL3759371 | 0.87 | PTGDR2 (0.57) | PDE4DPTGES2ERN1TSHRSMN1; SMN2 | |
| SCHEMBL29634014 | 0.86 | PDE4B (0.51) | PDE4DPDE4BNPC1MAPTTSHR | |
| SCHEMBL3796770 | 0.86 | PDE4B (0.51) | PDE4DPDE4BNPC1MAPTTSHR | |
| SCHEMBL29633976 | 0.86 | PDE4B (0.51) | PDE4DPDE4BPTGES2ERN1NPC1 | |
| SCHEMBL3841461 | 0.86 | PDE4D (0.52) | PDE4DPDE4BPTGES2NPC1MAPT | |
| SCHEMBL8066084 | 0.86 | PDE4B (0.51) | PDE4DPDE4BPTGES2NPC1MAPT | |
| SCHEMBL3797410 | 0.85 | HTR7 (0.55) | PDE4DPDE4BMAPK10RORCRORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323570-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| US-7211595-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | PDE4D 4241/4885PDE4B 3120/4885PTGES2 3860/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | PDE4D 3750/4885PDE4B 2527/4885PTGES2 1935/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | PDE4D 3965/4885PDE4B 2885/4885PTGES2 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.